[2]PARDOLL DM. The blockade of immune checkpoints in cancer immunotherapy[J]. Nat Rev Cancer, 2012, 12(4): 252-264. DOI: 10.1038/nrc3239 [3]EL-KHOUEIRY AB, SANGRO B, YAU T, et al. Nivolumab in patients with advanced hepatoc...
1.Laura Strauss et al. Targeted deletion of PD-1 in myeloid cells induces antitumor immunity. Science Immunology, 2020, doi:10.1126/sciimmunol.aay1863.2.Christopher E. Rudd. A new perspective in cancer immunotherapy: PD-1 on myeloid cells takes center stage in orchestrating immune checkpoint ...
monotherapy in patients with previously treated advanced gastric cancer. 5.sandip pravin patel, razelle kurzrock. pd-l1 expression as a predictive biomarker in cancer immunotherapy. molcancer ther. 2015 feb 18. 6.sol...
[2]PARDOLL DM. The blockade of immune checkpoints in cancer immunotherapy[J]. Nat Rev Cancer, 2012, 12(4): 252-264. DOI: 10.1038/nrc3239 [3]EL-KHOUEIRY AB, SANGRO B, YAU T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-co...
Although, recent reports support the presence of tumor infiltrating lymphocytes (TILs) in breast cancer that make it favorable for PD-1/PD-L1 mediated immunotherapy, which is effective in PD-L1 positive patients. Recently, anti-PD-1 (pembrolizumab) and anti-PD-L1 (atezolizumab) gets FDA ...
《Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy》 《PD-L1 expression by dendritic cells is a keyregulator of T-cell immunity in cancer》 文献1 Science的子刊《ScienceTranslationalMedicine》 PD-L1/PD-1阻断抗体已证明对一系列人类癌症具有治疗效果。然而,将这种益处扩大到更多的患...
PD-1/PD-L1检查点抑制剂不再是简单“增强”免疫反应,而是让肿瘤发病过程中出现缺陷的免疫系统“恢复正常”。“恢复正常”的免疫系统可以使部分患者实现长期生存获益,由于单药PD-1/PD-L1检查点抑制剂的客观缓解率仅为20%左右,使得获益人群有限。 (A Paradigm Shift in Cancer Immunotherapy: From Enhancement to No...
不仅肿瘤细胞表达PD-L1，有些免疫细胞也表达该分子。例如，抗原递呈细胞树突状细胞和巨噬细胞也表达PD-L1，它们可能用PD-L1来防止T细胞的过度活化。根据这方面的理论，也许可以部分解释为何有些PD-L1阴性的患者也可以对PD-1/PD-L1抑制剂有效。图片来源：Cancer Immunotherapy Using Checkpoint Blockade. Science. 2018...
23): 5591-5596.2. Pardoll D M. The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews Cancer, 2012, 12(4): 252-264.3. Boussiotis V A. Molecular and biochemical aspects of the PD-1 checkpoint pathway.New England Journal of Medicine, 2016, 375(18): 1767-1778.
摘要: Inhibiting the protein PD-1 can activate T cells that trigger immune responses against tumour cells. But it emerges that, in mice, this immunotherapy exacerbates a cancer that involves the T cells themselves. See Letter p.121DOI: 10.1038/nature24759 被引量: 5 ...